Fibromyalgia Diagnosis Criteria: A Comprehensive Guide for Clinicians

Introduction

Fibromyalgia is a prevalent chronic pain disorder characterized by widespread musculoskeletal pain accompanied by a constellation of symptoms including fatigue, cognitive dysfunction, sleep disturbances, and mood disorders like anxiety and depression.[1] Effective diagnosis and management are crucial for alleviating patient suffering, minimizing disability, and improving overall quality of life. Fibromyalgia is now understood as a disorder of pain regulation, influenced by a complex interplay of genetic predisposition, environmental factors, and neurobiological mechanisms.[2, 3] Central sensitization, a process involving altered pain signal processing within the central nervous system (CNS), is recognized as a key feature in the pathophysiology of fibromyalgia.[4]

Neuroimaging studies have consistently demonstrated an amplified pain response to stimuli in fibromyalgia patients, alongside alterations in neurotransmitter function and structural changes in brain connectivity. These findings underscore the significant role of CNS dysfunction in this condition.[5] Clinically, fibromyalgia presents with chronic, widespread pain lasting for more than three months, often coupled with fatigue, sleep problems, and cognitive or psychiatric symptoms. Diagnosis relies primarily on clinical evaluation, guided by established criteria such as the American College of Rheumatology (ACR) criteria. In children and adolescents, juvenile primary fibromyalgia syndrome (JPFS) is diagnosed using criteria like the Yunis and Masi criteria.

While routine lab tests and imaging are typically normal in fibromyalgia and are not diagnostic, they are essential to exclude other conditions that may mimic or contribute to the patient’s symptoms. A careful diagnostic assessment is vital to determine the need for further investigations. Management requires a holistic, multidisciplinary approach combining non-pharmacological strategies, such as patient education, exercise, and psychological therapies, with pharmacological interventions. Medications like duloxetine, milnacipran, pregabalin, and amitriptyline have shown some benefit in symptom management.[6] Conversely, NSAIDs, acetaminophen, and opioids are generally discouraged due to limited efficacy and potential risks.

Etiology of Fibromyalgia

The exact cause of fibromyalgia remains elusive, and it is considered a multifactorial condition. Current understanding points towards a combination of physical and emotional stressors acting as triggers or exacerbating factors for underlying pain processing abnormalities.[7, 8] Fibromyalgia is fundamentally considered a disorder of central sensitization, where the CNS amplifies pain signals.[9, 10]

Central sensitization results in heightened pain sensitivity. Individuals with fibromyalgia perceive normally non-painful stimuli as painful (allodynia) and experience exaggerated pain responses to painful stimuli (hyperalgesia).[11] Temporal summation, an increased pain intensity with repeated short noxious stimuli, is also observed in fibromyalgia patients, possibly due to deficits in endogenous pain modulation systems.[10, 12] Neuroimaging studies further support these central nervous system changes, revealing altered activity in brain regions involved in pain processing.

Genetic factors are also thought to play a role in fibromyalgia susceptibility, although no single gene has been definitively identified.[13] Individuals with a first-degree relative with fibromyalgia have a significantly increased risk (approximately 13.6 times higher) of developing the condition themselves.[14] Several genes are under investigation as potential contributors, including COMT, genes related to opioid receptors, voltage-gated channels, and GABAergic pathways.[13] Genome-wide studies have identified associations between chronic widespread pain and specific genetic loci, such as RNF123 and ATP2C1, which are involved in calcium regulation.[15]

Epidemiology of Fibromyalgia

Fibromyalgia affects approximately 2% to 3% of the population in the United States and worldwide, with prevalence increasing with age.[1, 16, 17] It is most commonly diagnosed in women between 20 and 55 years old and is a leading cause of widespread musculoskeletal pain in women. Adult women are about twice as likely as men to receive a fibromyalgia diagnosis. Notably, within tertiary pain management clinics, fibromyalgia criteria are met in over 40% of referred patients.[18] The presence of pre-existing rheumatic conditions increases the risk of developing fibromyalgia.

Juvenile primary fibromyalgia syndrome (JPFS) prevalence ranges from 1% to 6% among school-aged children and adolescents globally, accounting for a significant proportion (7% to 15%) of pediatric rheumatology clinic referrals.[19, 20] JPFS is also predominantly diagnosed in females (approximately 84%), with a typical diagnostic age range of 9 to 20 years and a mean age around 15.4 years.[21] While JPFS is more frequently diagnosed in non-Hispanic White individuals, it’s important to acknowledge potential biases in these statistics due to underdiagnosis and undertreatment of pain in certain ethnic groups.

Pathophysiology of Fibromyalgia: Central Sensitization in Detail

The experience of pain is a complex process involving the transmission and integration of nociceptive signals from the spinal cord to various brain regions, often referred to as “pain hubs.” This process is modulated by somatic reflexes and influenced by emotional, motivational, and cognitive factors. The hypothalamic-pituitary-adrenocortical (HPA) axis and the sympathetic nervous system (SNS), the body’s primary stress response regulators, also play a critical role. In fibromyalgia, disruptions in functional brain connectivity and neurochemical imbalances within the pain-processing system are evident.

Autonomic Nervous System Dysfunction

Autonomic nervous system (ANS) dysfunction, characterized by reduced heart rate variability (HRV) and alterations in skin conductance, is believed to contribute to the symptom complex of fibromyalgia. This dysfunction, coupled with an overactive stress response and HPA axis dysregulation, may explain the links between pain, sleep disturbances, mood symptoms, and cognitive difficulties. Some studies have reported reduced basal cortisol levels, decreased urinary cortisol excretion, and blunted cortisol responses to stimulation tests in fibromyalgia patients.[22, 23] However, meta-analyses indicate that while an association between fibromyalgia and HPA-axis dysfunction exists, findings are not entirely consistent and may be influenced by study design and patient populations. Therefore, conclusive evidence for abnormal HPA-axis function in all fibromyalgia patients remains debated.[24] Reduced HRV, indicative of heightened sympathetic nervous system activity, along with changes in skin conductance and sweating, are observed as physical manifestations of autonomic dysfunction.

Central Nervous System Dysfunction: Structural and Functional Brain Changes

Changes in Brain Morphology and Function: Magnetic resonance imaging (MRI) studies have revealed structural brain changes in fibromyalgia patients, including:

• Reduced Gray Matter Volume: Most notably in the anterior cingulate cortex and prefrontal cortex, areas involved in pain modulation and cognitive functions.
• Premature Brain Aging: Evidenced by an accelerated rate of age-related gray matter loss.
• Decreased Cortical Thickness and Functional Connectivity: Particularly in the rostral anterior cingulate cortex, impacting pain processing and emotional regulation.[25, 26, 27]

These structural changes tend to become more pronounced with increasing disease duration.

Changes in Neurotransmitters: In healthy individuals, the ventral tegmental area, a region regulating sensory, affective, cognitive, and pain-modulatory processes, activates during pain anticipation and stimulation and deactivates upon anticipating pain relief. However, functional MRI (fMRI) studies in fibromyalgia patients show reduced activation in this area, suggesting altered dopaminergic and GABAergic neurotransmission.[28] Elevated glutamate levels in the right posterior insular region have also been correlated with a decreased pain threshold.[29] Transcranial magnetic stimulation studies indicate deficits in intracortical GABAergic and glutamatergic modulation in fibromyalgia.[30, 31] Furthermore, studies have shown increased neuronal activity in pain-processing brain regions in fibromyalgia patients compared to healthy controls.[32, 33] Brain network analysis reveals alterations in the structure of brain hubs, which are critical for integrating information across different brain regions. [34]

Changes in the insular hub topology are linked to pain intensity in fibromyalgia, indicating a disruption in neural network stability compared to healthy individuals. Elevated levels of inositol, another neurotransmitter-related molecule, in the amygdala and thalamus are also found in fibromyalgia patients, correlating with increased pain, fatigue, and depression symptoms.

Changes in Resting-State Functional Connectivity: Fibromyalgia patients exhibit altered resting-state functional connectivity in brain regions involved in pain modulation. Specifically, altered connectivity of the periaqueductal gray, a key area in descending pain inhibition, suggests impaired pain modulation.[35] Altered connectivity is also observed between the default mode network (DMN), involved in self-referential thought and introspection, and the insula, a core pain-processing region. Furthermore, changes in connectivity are seen between DMN structures and the anterior midcingulate cortex, right parahippocampal gyrus, left superior parietal lobule, and left inferior temporal gyrus.

Reduced functional connectivity between the DMN and the right parahippocampal gyrus is associated with longer symptom duration. Conversely, enhanced connectivity between the anterior midcingulate and posterior cingulate cortices correlates with higher pain and depression scores. Imbalanced activity between the ventral and dorsal cervical spinal cord may also contribute to central sensitization and the somatic symptoms of fibromyalgia, including fatigue.[36]

Sleep Abnormalities

Sleep disturbance is a hallmark symptom of fibromyalgia, with phasic α-sleep, an intrusion of alpha waves into delta sleep, being a characteristic polysomnographic finding. Some research suggests sleep problems may precede the onset of widespread pain. A Norwegian study identified non-restorative sleep as the strongest predictor of widespread pain, and sleep disruption is considered a risk factor for fibromyalgia development.[37] Sleep disturbances significantly impact attention, cognition, and pain severity.[38]

Small Fiber Neuropathy

Small fiber neuropathy, often manifesting as hyperesthesia in a stocking-glove distribution, is frequently observed in fibromyalgia patients. Central sensitization may contribute to the development of small fiber neuropathy in some individuals. Elevated glutamate levels in the insula may contribute to pain and reduced intraepidermal nerve fiber density, as seen in some fibromyalgia patients. Skin biopsies in patients with small fiber neuropathy can reveal reduced intraepidermal nerve fiber density or altered electrochemical skin conductance.

History and Physical Examination in Fibromyalgia Diagnosis

A detailed history and physical examination are crucial for the initial evaluation of patients presenting with widespread musculoskeletal pain, fatigue, and sleep disturbances. This process helps clinicians differentiate fibromyalgia from other conditions and identify co-existing conditions that might mimic or worsen fibromyalgia symptoms.

Widespread Musculoskeletal Pain: The Defining Symptom

The cardinal symptom of fibromyalgia is chronic, widespread musculoskeletal pain lasting at least three months. Patients often describe the pain as a deep ache, but it can also be characterized as dull, sharp, shooting, or burning. Common patient descriptions include “I hurt all over” or “It feels like I constantly have the flu.” While the pain is primarily musculoskeletal, patients may also report joint pain and perceived swelling, even in the absence of synovitis or objective joint abnormalities on examination.[3, 39, 40] Pain may initially be localized, often in the neck and shoulders, but typically becomes widespread, affecting at least six soft tissue sites in the upper and lower body. The 1990 ACR classification criteria identified specific tender point sites, including the upper trapezius, lateral epicondyle, second costochondral junction, and greater trochanter. Pain can also involve the head, lower back, buttocks, and abdomen. Morning stiffness is common, and pain is often exacerbated by minimal activity or prolonged inactivity. Approximately 25% of children with JPFS may exhibit joint hypermobility.[41]

Fatigue and Sleep Disturbances

Debilitating fatigue and sleep disturbances are core features of fibromyalgia.[42] Similar to pain, fatigue is often worsened by mild to moderate activity or prolonged inactivity.[43] Patients typically report non-restorative sleep, light sleep, frequent awakenings (especially early morning), difficulty falling back asleep, and feeling unrefreshed upon waking.

Cognitive Dysfunction (“Fibro Fog”)

Cognitive disturbances are common in fibromyalgia, often described as “fibro fog.” Patients frequently report difficulty concentrating, memory problems, and impaired ability to perform tasks requiring rapid processing speed.[44]

Psychiatric Comorbidities

Depression and anxiety are highly prevalent in fibromyalgia, affecting 30% to 50% of patients.[45, 46, 47, 48] Bipolar disorder, posttraumatic stress disorder (PTSD), and personality traits like catastrophizing and alexithymia are also more common in fibromyalgia populations.[47] Systematic reviews have found that a significant proportion of fibromyalgia patients have a history of bipolar disorder, panic disorder, or PTSD.[47, 49]

Other Associated Symptoms

In addition to the core symptoms, fibromyalgia patients often experience a range of somatic complaints. Headaches, including tension headaches, cluster headaches, and migraines, are common, affecting approximately 50% of patients.[50] Paresthesias, particularly in the arms and legs, are frequently reported despite a normal neurological examination. In some cases, small fiber neuropathy can be confirmed by skin biopsy. Significant symptom overlap exists between JPFS, pediatric hypermobility syndromes, and juvenile idiopathic arthritis.

Other symptoms and conditions commonly associated with fibromyalgia include:

• Irritable bowel syndrome (IBS)
• Gastroesophageal reflux disease (GERD)
• Dry eyes
• Dyspnea (shortness of breath)
• Dysphagia (difficulty swallowing)
• Palpitations
• Autonomic dysfunction (Raynaud phenomenon, orthostatic hypotension, altered HRV)
• Hearing loss
• Dry eye syndrome
• Temporomandibular joint disorder (TMJ)
• Chest wall pain
• Pelvic pain
• Hyperesthesia (increased sensitivity) in a stocking distribution
• Urinary urgency and frequency (consistent with painful bladder syndrome) [51, 52, 53]

Evaluation and Diagnostic Criteria for Fibromyalgia

Fibromyalgia should be suspected in patients presenting with the characteristic constellation of widespread musculoskeletal pain, sleep disturbances, fatigue, cognitive impairment, psychiatric symptoms, and somatic complaints.[54] The diagnostic process begins with a thorough patient history and physical examination. Clinicians should carefully assess pain characteristics (location, quality, duration), sleep patterns, fatigue severity, psychiatric symptoms, and cognitive function. It is also essential to screen for comorbid conditions and rule out other potential diagnoses like inflammatory arthritis, osteoarthritis, thyroid disease, and localized pain syndromes.

The physical examination should include a comprehensive joint and neurological assessment. Palpation of multiple soft tissue sites and joints should be performed, noting tenderness in soft tissues without evidence of synovitis. Current fibromyalgia diagnostic guidelines, except for the Yunis and Masi criteria, no longer emphasize the specific number of tender points or predefined tender point sites. Diagnosis is now primarily based on the presence of widespread or multisite soft tissue tenderness in at least 4 out of 5 body regions.

Laboratory and Imaging Tests

Laboratory or imaging tests are not used to diagnose fibromyalgia directly but are crucial for excluding other conditions. In adults, initial evaluation usually includes a complete blood count (CBC) and either a C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR). For children and adolescents, a basic metabolic panel and thyroid-stimulating hormone (TSH) are also recommended. Additional tests, such as 25-hydroxy vitamin D, vitamin B12, magnesium, iron studies, and creatine kinase levels, may be ordered based on clinical findings and specific symptoms to rule out other contributing factors. Routine rheumatoid factor and antinuclear antibody (ANA) testing should be avoided unless there are clinical signs suggestive of inflammatory rheumatic disease. Given the significant impact of sleep disturbances, sleep studies should be considered in patients suspected of obstructive sleep apnea or other primary sleep disorders. Tilt table testing to assess autonomic nervous system function may be warranted in patients with tachycardia, orthostasis, and palpitations, potentially involving referral to cardiology.

Fibromyalgia Diagnostic Criteria: Evolution and Current Standards

Several diagnostic criteria for fibromyalgia have been developed and refined over time. The initial 1990 ACR criteria heavily relied on a specific tender point count. However, standardization of tender point examination proved challenging, limiting its widespread use. Furthermore, the 1990 criteria did not adequately address the non-pain symptoms associated with fibromyalgia, such as somatic, psychiatric, and cognitive dysfunction. To address these limitations, the ACR updated the diagnostic guidelines in 2010. In 2016, the ACR further revised the criteria to include a generalized pain criterion, requiring pain in 4 out of 5 regions to reduce misclassification of regional pain syndromes as fibromyalgia. For diagnosing JPFS, clinicians can use either the Yunis and Masi criteria or the ACR criteria. The ACR criteria have demonstrated high sensitivity and specificity (88% to 89%) for JPFS diagnosis when compared to the Yunis and Masi criteria.[55]

Yunis and Masi Criteria for Juvenile Primary Fibromyalgia Syndrome (JPFS)

The Yunis and Masi criteria are specifically designed for diagnosing JPFS. Patients must meet all four major criteria and at least three of the ten minor criteria:

Major Criteria:

1. Generalized musculoskeletal aching at three or more sites for at least 3 months.
2. Absence of an underlying systemic condition or other identifiable cause for the symptoms.
3. Normal laboratory test results (to rule out other conditions).
4. Presence of five or more tender points on digital palpation.

Minor Criteria:

1. Chronic anxiety or tension
2. Sleep disturbance (non-restorative sleep)
3. Chronic headaches
4. Fatigue
5. Irritable bowel syndrome (IBS)
6. Subjective soft tissue swelling
7. Numbness or paresthesias
8. Pain modulation by physical activity (worsening with activity or inactivity)
9. Pain modulation by weather changes
10. Pain modulation by anxiety or stress

2010 American College of Rheumatology (ACR) Preliminary Diagnostic Criteria

The 2010 ACR preliminary diagnostic criteria shifted away from tender point counts and incorporated symptom severity scales:

• Diagnostic Criteria:
  1. Widespread Pain Index (WPI) score of ≥ 7 and Symptom Severity (SS) score of ≥ 5, OR WPI score of 3-6 and SS score of ≥ 9.
  2. Symptoms present at a similar level for at least 3 months.
  3. No other disorder that would solely account for the pain.

The WPI assesses the number of painful body regions out of 19 possible sites. The SS score quantifies the severity of fatigue, cognitive problems, and somatic symptoms. Detailed information on the WPI and SS scoring can be found on the American College of Rheumatology website (link provided in original article).

2016 American College of Rheumatology (ACR) Revised Diagnostic Criteria

The 2016 ACR revised criteria further refined the 2010 criteria by adding a generalized pain criterion:

• Diagnostic Criteria:
  1. Widespread Pain Index (WPI) score of ≥ 7 and Symptom Severity (SS) score of ≥ 5, OR WPI score of 4-6 and SS score of ≥ 9.
  2. Generalized pain, defined as pain in at least 4 out of 5 regions. (Regions: right upper, left upper, axial, right lower, left lower – excluding jaw, chest, and abdomen in the regional count).
  3. Symptoms have been present at a similar level for at least 3 months.

ACTTION-APS Pain Taxonomy (AAPT) Criteria

The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) in collaboration with the FDA and APS, developed the AAPT diagnostic system for chronic pain, including fibromyalgia. The 2019 AAPT criteria for fibromyalgia include:

• Core Criteria:
  1. Multisite pain: Pain in 6 or more sites out of 9 possible sites (head, left arm, right arm, chest, abdomen, upper back and spine, lower back and spine including buttocks, left leg, right leg).
  2. Moderate-to-severe sleep problems or fatigue.
  3. Both criteria must be present for at least 3 months.

The AAPT criteria acknowledge that fibromyalgia can co-exist with other pain disorders. However, a comprehensive clinical assessment is always necessary to identify any other condition that could fully explain the patient’s symptoms or contribute to their severity.

Clinical Judgment Remains Paramount: It is crucial to emphasize that fibromyalgia diagnosis remains primarily clinical. While these diagnostic criteria are valuable tools to aid in diagnosis, they should not replace careful clinical judgment and a thorough evaluation of each patient’s unique presentation.

Treatment and Management Strategies for Fibromyalgia

Effective fibromyalgia management necessitates a multimodal approach, integrating both pharmacological and non-pharmacological therapies. The primary goals of treatment are to alleviate symptoms and empower patients with self-management strategies to improve their daily functioning and quality of life.

Key Treatment Goals:

• Reduce core fibromyalgia symptoms: chronic pain, fatigue, sleep disturbances, and mood disorders.
• Enhance patient self-efficacy through education and non-pharmacological interventions.
• Personalize treatment plans to address individual symptom profiles and comorbidities.
• Manage co-existing conditions that can impact fibromyalgia symptoms or treatment adherence.

Treatment plans should be individualized, considering patient preferences, comorbidities, and potential barriers to care, such as socioeconomic factors, medication costs, and prior treatment experiences.

Non-Pharmacological Therapies: Cornerstones of Fibromyalgia Management

Non-pharmacological approaches form the foundation of fibromyalgia treatment, emphasizing patient education, cognitive behavioral therapy (CBT), and physical activity.

Patient Education: A critical first step is to validate the patient’s experience and reassure them that fibromyalgia is a genuine medical condition. Educating patients about the nature of fibromyalgia, particularly the concept of central sensitization and the difference between nociceptive pain and centralized pain, is essential. It is important to explain that fibromyalgia is not due to tissue damage in the same way as arthritis, but rather a dysregulation of pain processing in the nervous system. Patients should understand that both central and peripheral pain mechanisms can interact and exacerbate each other. Setting realistic expectations for treatment outcomes is crucial to prevent frustration. Patients should be informed that while there is no cure, effective management strategies can significantly improve symptoms and function, although some level of pain and fatigue may persist, and symptom fluctuations are common.

Addressing comorbid conditions is also vital. Patients with depression, anxiety, and sleep disorders should be encouraged to seek treatment for these conditions, as they can significantly worsen fibromyalgia symptoms and vice versa. Screening for sleep apnea and restless legs syndrome is important, and patients with suspected primary sleep disorders should be referred to sleep specialists. Emphasis on sleep hygiene is a key component of patient education.

Recommended Sleep Hygiene Practices:

• Maintain a regular sleep schedule: go to bed and wake up at the same time each day.
• Create a conducive sleep environment: dark, quiet, and cool bedroom.
• Limit caffeine intake, especially after lunch.
• Avoid alcohol close to bedtime.
• Restrict electronic device use (phones, tablets, computers) 30-60 minutes before bed.
• Avoid strenuous exercise within 2 hours of bedtime.
• Avoid nicotine.
• Avoid heavy meals close to bedtime.

Physical Activity and Exercise: Regular exercise is a cornerstone of fibromyalgia management. It can effectively reduce pain, improve sleep quality, and alleviate fatigue. Cardiovascular fitness training, resistance training, and movement therapies like Tai Chi have demonstrated significant benefits. Exercise programs should be individualized, starting with low-impact aerobic exercises such as walking, swimming, cycling, or water aerobics, unless contraindicated.[56, 57, 58] The recommended target is at least 30 minutes of aerobic exercise three times per week. However, patients should be encouraged to engage in exercise at a level they can sustain, even if it is initially less than the recommended target. It is important to counsel patients that they may experience a temporary increase in pain and fatigue when starting an exercise program, and gradually increasing activity levels can help minimize these effects.

Cognitive Behavioral Therapy (CBT) and Psychological Therapies: Cognitive therapies, including CBT, mindfulness-based stress reduction, and relaxation techniques, are valuable non-pharmacological treatments for fibromyalgia. CBT has been shown to reduce pain, sleep disturbances, and symptoms of depression and anxiety, particularly when combined with patient education.[59, 60, 61] Accessibility and cost can sometimes be barriers to CBT. Online and telephone-based CBT programs can improve access for many patients.

Pharmacological Therapy: Medications for Symptom Management

Pharmacological therapy should be considered for patients with moderate to severe fibromyalgia symptoms, or when non-pharmacological approaches alone are insufficient. Patients should be informed that medications are moderately effective in approximately 50% of cases.[6] First-line medications include tricyclic antidepressants (TCAs) such as amitriptyline, selective norepinephrine reuptake inhibitors (SNRIs) like duloxetine and milnacipran, and α-2 ligands such as pregabalin and gabapentin.[62] Cyclobenzaprine, another tricyclic medication, can also be effective.

Medication choice should be guided by the patient’s specific symptoms and comorbidities. For patients with primarily widespread pain without significant mood symptoms, a TCA like amitriptyline, started at a low dose (5-10 mg at bedtime), is often a good initial option. The dose can be gradually increased every 2 weeks as needed, with a typical effective dose range of 20-30 mg. Treatment duration of 12 months followed by a weaning trial may be considered. Cyclobenzaprine is an alternative, starting at 5 mg at bedtime and increasing to 10-20 mg as needed.

SNRIs, duloxetine and milnacipran, are appropriate for patients with significant fatigue or depression alongside pain.

SNRI Dosing:

• Duloxetine: Approved for adults and adolescents (13 years and older). Starting dose 20-30 mg daily in the morning with food, gradually increasing to a maximum of 60 mg daily. Average effective dose is 60 mg/day. Important warning: Antidepressants may increase the risk of suicidal thoughts and behaviors, especially in children and young adults. Monitor closely for changes in mood or behavior.
• Milnacipran: Starting dose 12.5 mg daily, gradually increased every few weeks to a maximum of 50-100 mg daily, taken once or twice daily. Average effective dose is 100 mg/day.

Pregabalin is often a first-line option for patients with widespread pain and significant sleep disturbances. Gabapentin is a suitable alternative when cost or access limits pregabalin use.

α-2 Ligand Dosing:

• Pregabalin: Starting dose 25-50 mg at bedtime, titrated by 25-50 mg every 2-4 weeks. Can be given once nightly or divided twice daily. Typical recommended dose range is 300-450 mg/day.
• Gabapentin: Starting dose 100 mg at bedtime, gradually titrating in 100 mg increments every few weeks. Recommended daily dose range is 1200-2400 mg, divided into up to three doses daily.[63]

Pregabalin and gabapentin are used off-label in children and adolescents and may be effective, but more research is needed to establish specific pediatric recommendations.

Managing Persistent Symptoms and Alternative Therapies

If the initial medication is not sufficiently effective, switching to a different medication class is a reasonable next step. When discontinuing fibromyalgia medications, especially at moderate to high doses, gradual tapering is essential to prevent withdrawal symptoms. If monotherapy with different agents remains ineffective, combination therapy with lower doses of medications from different classes may be considered. Common combinations include an SNRI in the morning with a low-dose TCA at bedtime, or an SNRI with a low-dose α-2 ligand.

Other Therapeutic Options:

• Selective Serotonin Reuptake Inhibitors (SSRIs): Evidence for SSRIs like fluoxetine, paroxetine, and fluvoxamine in fibromyalgia is limited. They may be considered for patients who cannot tolerate or do not respond to first-line therapies.
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Generally not recommended for fibromyalgia due to limited efficacy.
• Opioids: Opioids should generally be avoided in fibromyalgia. Tramadol, a weak opioid with SNRI properties, may be considered in refractory cases.
• Low-Dose Naltrexone (LDN): LDN (typically 5 mg) is used for chronic pain management, potentially by upregulating endogenous opioid production.[65, 66, 67]
• Nutrition: No specific dietary guidelines exist for fibromyalgia. However, weight loss in overweight or obese patients can improve pain and depression. Plant-based and low-FODMAP diets may also show some benefit, but further research is needed.[68, 69]
• Acupuncture: Moderate evidence supports acupuncture as an effective treatment for fibromyalgia.[70]
• Neuromodulation: Transcutaneous Electrical Nerve Stimulation (TENS), transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS) have shown some benefit in reducing pain and fatigue.[71, 72, 73]
• Trigger Point Injections: May offer short-term relief for localized pain in some patients.[74]
• Massage Therapy: Regular massage therapy can be beneficial for managing fibromyalgia symptoms.[75]

Differential Diagnosis of Fibromyalgia

Fibromyalgia shares overlapping symptoms with several other conditions, necessitating a careful differential diagnosis. These include:

• Polymyalgia rheumatica
• Spondyloarthritis
• Myositis
• Hypothyroidism
• Hyperparathyroidism
• Neuropathies
• Systemic lupus erythematosus (SLE)
• Chronic fatigue syndrome (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – ME/CFS)
• Hepatitis
• Vitamin B12 deficiency
• Vitamin D deficiency
• Myofascial pain syndrome
• Hereditary myopathies
• Complex regional pain syndrome (CRPS)
• Dermatomyositis
• Juvenile idiopathic arthritis (JIA)
• Chronic noninfectious osteomyelitis

Prognosis and Long-Term Outcomes

Fibromyalgia significantly impacts quality of life in both children and adults.[76] Long-term outcomes for JPFS into adulthood are still being studied, but evidence suggests that symptoms often persist into early adulthood.[77, 78] Similarly, adult fibromyalgia is typically a chronic condition with fluctuating symptom severity. Patients treated in tertiary care centers may have a less favorable prognosis compared to those managed in primary care settings.[79, 80]

Factors associated with poorer prognosis include depression, history of abuse, catastrophizing, and multiple somatic complaints. Female sex, low socioeconomic status, longer disease duration, untreated mood disorders, substance dependence, high stress levels, and unemployment also contribute to disease burden. Fibromyalgia is associated with disability rates of 10% to 30% and an increased risk of suicide.[81]

Complications of Fibromyalgia

Fibromyalgia increases the risk of metabolic syndrome, potentially due to reduced physical activity. Patients also have higher rates of disability and suicide compared to the general population. Recent research suggests an elevated risk of mortality from accidents and infections.[82]

Consultations and Interprofessional Care

Specialty consultations, including rheumatology, physiatry, physical therapy, and psychiatry, are essential for patients with diagnostic uncertainty or those who do not respond adequately to initial treatment. Interprofessional collaboration is crucial for comprehensive fibromyalgia management. Physicians, advanced practitioners, nurses, pharmacists, physical therapists, and mental health professionals all play vital roles in patient education, symptom management, and improving patient outcomes. Effective communication and coordinated care are essential for optimizing patient-centered care in fibromyalgia.

Deterrence and Patient Education: Empowering Patients

Patient education is paramount for effective fibromyalgia management. Clinicians should emphasize that fibromyalgia is a chronic condition but not life-threatening or degenerative. Validating patient experiences, reassuring them that their condition is real, and providing clear explanations about fibromyalgia pathophysiology can reduce frustration and feelings of invalidation. Lifestyle modifications, including regular low-impact exercise, stress management techniques, consistent sleep schedules, and cognitive therapy, should be emphasized as core strategies for long-term symptom management and improved quality of life.

References

[List of references as provided in the original article, in markdown format]

1.Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F. The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. PLoS One. 2015;10(9):e0138024. [PMC free article: PMC4575027] [PubMed: 26379048]

2.Goldenberg DL. Fibromyalgia syndrome. An emerging but controversial condition. JAMA. 1987 May 22-29;257(20):2782-7. [PubMed: 3553636]

3.Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014 Apr 16;311(15):1547-55. [PubMed: 24737367]

4.Pomares FB, Funck T, Feier NA, Roy S, Daigle-Martel A, Ceko M, Narayanan S, Araujo D, Thiel A, Stikov N, Fitzcharles MA, Schweinhardt P. Histological Underpinnings of Grey Matter Changes in Fibromyalgia Investigated Using Multimodal Brain Imaging. J Neurosci. 2017 Feb 01;37(5):1090-1101. [PMC free article: PMC6596849] [PubMed: 27986927]

5.Ricci M, Cimini A, Grivet Fojaja MR, Ullo M, Carabellese B, Frantellizzi V, Lubrano E. Novel Approaches in Molecular Imaging and Neuroimaging of Fibromyalgia. Int J Mol Sci. 2022 Dec 08;23(24) [PMC free article: PMC9778683] [PubMed: 36555158]

6.Ben-Ami Shor D, Weitzman D, Dahan S, Gendelman O, Bar-On Y, Amital D, Shalev V, Chodick G, Amital H. Adherence and Persistence with Drug Therapy among Fibromyalgia Patients: Data from a Large Health Maintenance Organization. J Rheumatol. 2017 Oct;44(10):1499-1506. [PubMed: 28765248]

7.Sarzi-Puttini P, Atzeni F, Mease PJ. Chronic widespread pain: from peripheral to central evolution. Best Pract Res Clin Rheumatol. 2011 Apr;25(2):133-9. [PubMed: 22094190]

8.Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol. 2011 Jul 19;7(9):518-27. [PubMed: 21769128]

9.Dadabhoy D, Crofford LJ, Spaeth M, Russell IJ, Clauw DJ. Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther. 2008;10(4):211. [PMC free article: PMC2575617] [PubMed: 18768089]

10.Staud R. Abnormal pain modulation in patients with spatially distributed chronic pain: fibromyalgia. Rheum Dis Clin North Am. 2009 May;35(2):263-74. [PMC free article: PMC2720882] [PubMed: 19647141]

11.Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, Finckh A, Cohen P, Dayer P, Vischer TL. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum. 2003 May;48(5):1420-9. [PubMed: 12746916]

12.O’Brien AT, Deitos A, Triñanes Pego Y, Fregni F, Carrillo-de-la-Peña MT. Defective Endogenous Pain Modulation in Fibromyalgia: A Meta-Analysis of Temporal Summation and Conditioned Pain Modulation Paradigms. J Pain. 2018 Aug;19(8):819-836. [PubMed: 29454976]

13.Buskila D, Sarzi-Puttini P. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther. 2006;8(5):218. [PMC free article: PMC1779444] [PubMed: 16887010]

14.D’Agnelli S, Arendt-Nielsen L, Gerra MC, Zatorri K, Boggiani L, Baciarello M, Bignami E. Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers. Mol Pain. 2019 Jan-Dec;15:1744806918819944. [PMC free article: PMC6322092] [PubMed: 30486733]

15.Rahman MS, Winsvold BS, Chavez Chavez SO, Børte S, Tsepilov YA, Sharapov SZ, HUNT All-In Pain. Aulchenko YS, Hagen K, Fors EA, Hveem K, Zwart JA, van Meurs JB, Freidin MB, Williams FM. Genome-wide association study identifies RNF123 locus as associated with chronic widespread musculoskeletal pain. Ann Rheum Dis. 2021 Sep;80(9):1227-1235. [PMC free article: PMC8372387] [PubMed: 33926923]

16.Vincent A, Lahr BD, Wolfe F, Clauw DJ, Whipple MO, Oh TH, Barton DL, St Sauver J. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013 May;65(5):786-92. [PMC free article: PMC3935235] [PubMed: 23203795]

17.Kocyigit BF, Akyol A. Fibromyalgia syndrome: epidemiology, diagnosis and treatment. Reumatologia. 2022;60(6):413-421. [PMC free article: PMC9847104] [PubMed: 36683836]

18.Brill S, Ablin JN, Goor-Aryeh I, Hyat K, Slefer A, Buskila D., Tel Aviv-Sourasky Medical Center. Prevalence of fibromyalgia syndrome in patients referred to a tertiary pain clinic. J Investig Med. 2012 Apr;60(4):685-8. [PubMed: 22373664]

19.Coles ML, Weissmann R, Uziel Y. Juvenile primary Fibromyalgia Syndrome: epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis. Pediatr Rheumatol Online J. 2021 Mar 01;19(1):22. [PMC free article: PMC7923821] [PubMed: 33648522]

20.Weiss JE, Kashikar-Zuck S. Juvenile Fibromyalgia. Rheum Dis Clin North Am. 2021 Nov;47(4):725-736. [PubMed: 34635301]

21.Eraso RM, Bradford NJ, Fontenot CN, Espinoza LR, Gedalia A. Fibromyalgia syndrome in young children: onset at age 10 years and younger. Clin Exp Rheumatol. 2007 Jul-Aug;25(4):639-44. [PubMed: 17888225]

22.McLean SA, Williams DA, Stein PK, Harris RE, Lyden AK, Whalen G, Park KM, Liberzon I, Sen A, Gracely RH, Baraniuk JN, Clauw DJ. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology. 2006 Dec;31(12):2776-82. [PMC free article: PMC4831068] [PubMed: 16936702]

23.McBeth J, Silman AJ, Gupta A, Chiu YH, Ray D, Morriss R, Dickens C, King Y, Macfarlane GJ. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. Arthritis Rheum. 2007 Jan;56(1):360-71. [PubMed: 17195240]

24.Beiner E, Lucas V, Reichert J, Buhai DV, Jesinghaus M, Vock S, Drusko A, Baumeister D, Eich W, Friederich HC, Tesarz J. Stress biomarkers in individuals with fibromyalgia syndrome: a systematic review with meta-analysis. Pain. 2023 Jul 01;164(7):1416-1427. [PubMed: 36728497]

25.Cagnie B, Coppieters I, Denecker S, Six J, Danneels L, Meeus M. Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. Semin Arthritis Rheum. 2014 Aug;44(1):68-75. [PubMed: 24508406]

26.Kim DJ, Lim M, Kim JS, Son KM, Kim HA, Chung CK. Altered white matter integrity in the corpus callosum in fibromyalgia patients identified by tract-based spatial statistical analysis. Arthritis Rheumatol. 2014 Nov;66(11):3190-9. [PubMed: 25225152]

27.Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chizh BA, Bushnell MC. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci. 2007 Apr 11;27(15):4004-7. [PMC free article: PMC6672521] [PubMed: 17428976]

28.Loggia ML, Berna C, Kim J, Cahalan CM, Gollub RL, Wasan AD, Harris RE, Edwards RR, Napadow V. Disrupted brain circuitry for pain-related reward/punishment in fibromyalgia. Arthritis Rheumatol. 2014 Jan;66(1):203-12. [PMC free article: PMC4516215] [PubMed: 24449585]

29.Harris RE, Sundgren PC, Craig AD, Kirshenbaum E, Sen A, Napadow V, Clauw DJ. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum. 2009 Oct;60(10):3146-52. [PMC free article: PMC2827610] [PubMed: 19790053]

30.Mhalla A, de Andrade DC, Baudic S, Perrot S, Bouhassira D. Alteration of cortical excitability in patients with fibromyalgia. Pain. 2010 Jun;149(3):495-500. [PubMed: 20356675]

31.Wu XQ, Tan B, Du Y, Yang L, Hu TT, Ding YL, Qiu XY, Moutal A, Khanna R, Yu J, Chen Z. Glutamatergic and GABAergic neurons in the vLGN mediate the nociceptive effects of green and red light on neuropathic pain. Neurobiol Dis. 2023 Jul;183:106164. [PubMed: 37217103]

32.Napadow V, Harris RE. What has functional connectivity and chemical neuroimaging in fibromyalgia taught us about the mechanisms and management of ‘centralized’ pain? Arthritis Res Ther. 2014;16(5):425. [PMC free article: PMC4289059] [PubMed: 25606591]

33.Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002 May;46(5):1333-43. [PubMed: 12115241]

34.Kaplan CM, Schrepf A, Vatansever D, Larkin TE, Mawla I, Ichesco E, Kochlefl L, Harte SE, Clauw DJ, Mashour GA, Harris RE. Functional and neurochemical disruptions of brain hub topology in chronic pain. Pain. 2019 Apr;160(4):973-983. [PMC free article: PMC6424595] [PubMed: 30763287]

35.Fallon N, Chiu Y, Nurmikko T, Stancak A. Functional Connectivity with the Default Mode Network Is Altered in Fibromyalgia Patients. PLoS One. 2016;11(7):e0159198. [PMC free article: PMC4956096] [PubMed: 27442504]

36.Martucci KT, Weber KA, Mackey SC. Altered Cervical Spinal Cord Resting-State Activity in Fibromyalgia. Arthritis Rheumatol. 2019 Mar;71(3):441-450. [PMC free article: PMC6393192] [PubMed: 30281205]

37.McBeth J, Lacey RJ, Wilkie R. Predictors of new-onset widespread pain in older adults: results from a population-based prospective cohort study in the UK. Arthritis Rheumatol. 2014 Mar;66(3):757-67. [PMC free article: PMC4163719] [PubMed: 24574238]

38.Fang SC, Wu YL, Chen SC, Teng HW, Tsai PS. Subjective sleep quality as a mediator in the relationship between pain severity and sustained attention performance in patients with fibromyalgia. J Sleep Res. 2019 Dec;28(6):e12843. [PubMed: 30920084]

39.Björkegren K, Wallander MA, Johansson S, Svärdsudd K. General symptom reporting in female fibromyalgia patients and referents: a population-based case-referent study. BMC Public Health. 2009 Oct 31;9:402. [PMC free article: PMC2776598] [PubMed: 19878599]

40.Kang JH, Choi SE, Xu H, Park DJ, Lee JK, Lee SS. Comparison of the AAPT Fibromyalgia Diagnostic Criteria and Modified FAS Criteria with Existing ACR Criteria for Fibromyalgia in Korean Patients. Rheumatol Ther. 2021 Jun;8(2):1003-1014. [PMC free article: PMC8217352] [PubMed: 34021490]

41.Weiss JE, Schikler KN, Boneparth AD, Connelly M., CARRA Registry Investigators. Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Pediatr Rheumatol Online J. 2019 Jul 26;17(1):51. [PMC free article: PMC6660676] [PubMed: 31349785]

42.Aggarwal VR, McBeth J, Zakrzewska JM, Lunt M, Macfarlane GJ. The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int J Epidemiol. 2006 Apr;35(2):468-76. [PubMed: 16303810]

43.Fors EA, Wensaas KA, Helvik AS. Prevalence and characteristics of fibromyalgia according to three fibromyalgia diagnostic criteria: A secondary analysis study. Scand J Pain. 2024 Jan 01;24(1) [PubMed: 39372320]

44.Cigarán-Mendez M, Pacho-Hernández JC, Tejera-Alonso Á, Gómez-Calero C, Fernández-de-Las-Peñas C, Valera-Calero JA, Fernández-Palacios FG. Diagnostic Accuracy of Neurocognitive and Executive Functions to Discriminate Women With and Without Fibromyalgia Syndrome: A Secondary Analysis. J Clin Med. 2024 Oct 17;13(20) [PMC free article: PMC11508891] [PubMed: 39458147]

45.Fuller-Thomson E, Nimigon-Young J, Brennenstuhl S. Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey. Rheumatol Int. 2012 Apr;32(4):853-62. [PubMed: 21221590]

46.Løge-Hagen JS, Sæle A, Juhl C, Bech P, Stenager E, Mellentin AI. Prevalence of depressive disorder among patients with fibromyalgia: Systematic review and meta-analysis. J Affect Disord. 2019 Feb 15;245:1098-1105. [PubMed: 30699852]

47.Kleykamp BA, Ferguson MC, McNicol E, Bixho I, Arnold LM, Edwards RR, Fillingim R, Grol-Prokopczyk H, Turk DC, Dworkin RH. The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review. Semin Arthritis Rheum. 2021 Feb;51(1):166-174. [PubMed: 33383293]

48.Galvez-Sánchez CM, Reyes Del Paso GA, Duschek S. Cognitive Impairments in Fibromyalgia Syndrome: Associations With Positive and Negative Affect, Alexithymia, Pain Catastrophizing and Self-Esteem. Front Psychol. 2018;9:377. [PMC free article: PMC5874325] [PubMed: 29623059]

49.Bortolato B, Berk M, Maes M, McIntyre RS, Carvalho AF. Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology. Curr Mol Med. 2016;16(2):119-36. [PubMed: 26812920]

50.Calandre EP, Ordoñez-Carrasco JL, Slim M, Rico-Villademoros F, Garcia-Leiva JM. Comorbidity of migraine and fibromyalgia in patients with cluster headache: psychological burden and healthcare resource utilization. A cross-sectional study. J Oral Facial Pain Headache. 2024 Mar;38(1):32-39. [PMC free article: PMC11774279] [PubMed: 39788574]

51.Wang JC, Sung FC, Men M, Wang KA, Lin CL, Kao CH. Bidirectional association between fibromyalgia and gastroesophageal reflux disease: two population-based retrospective cohort analysis. Pain. 2017 Oct;158(10):1971-1978. [PubMed: 28683023]

52.Kang JH, Kim JK, Hong SH, Lee CH, Choi BY. Heart Rate Variability for Quantification of Autonomic Dysfunction in Fibromyalgia. Ann Rehabil Med. 2016 Apr;40(2):301-9. [PMC free article: PMC4855125] [PubMed: 27152281]

53.Chen CH, Yang TY, Lin CL, Chen CS, Lin WM, Kuo CN, Lin MC, Kao CH. Dry Eye Syndrome Risks in Patients With Fibromyalgia: A National Retrospective Cohort Study. Medicine (Baltimore). 2016 Jan;95(4):e2607. [PMC free article: PMC5291583] [PubMed: 26825913]

54.Bennett RM. Clinical manifestations and diagnosis of fibromyalgia. Rheum Dis Clin North Am. 2009 May;35(2):215-32. [PubMed: 19647138]

55.Kashikar-Zuck S, Ting TV. Juvenile fibromyalgia: current status of research and future developments. Nat Rev Rheumatol. 2014 Feb;10(2):89-96. [PMC free article: PMC4470499] [PubMed: 24275966]

56.Busch AJ, Webber SC, Richards RS, Bidonde J, Schachter CL, Schafer LA, Danyliw A, Sawant A, Dal Bello-Haas V, Rader T, Overend TJ. Resistance exercise training for fibromyalgia. Cochrane Database Syst Rev. 2013 Dec 20;2013(12):CD010884. [PMC free article: PMC6544808] [PubMed: 24362925]

57.Bidonde J, Busch AJ, Webber SC, Schachter CL, Danyliw A, Overend TJ, Richards RS, Rader T. Aquatic exercise training for fibromyalgia. Cochrane Database Syst Rev. 2014 Oct 28;2014(10):CD011336. [PMC free article: PMC10638613] [PubMed: 25350761]

58.Neelapala YVR, Mercuri D, Macedo L, Hanna S, Kobsar D, Carlesso L. Mechanisms hypothesized for pain-relieving effects of exercise in fibromyalgia: a scoping review. Ther Adv Musculoskelet Dis. 2023;15:1759720X231182894. [PMC free article: PMC10356998] [PubMed: 37484924]

59.Prados G, Miró E, Martínez MP, Sánchez AI, Lami MJ, Cáliz R. Combined cognitive-behavioral therapy for fibromyalgia: Effects on polysomnographic parameters and perceived sleep quality. Int J Clin Health Psychol. 2020 Sep-Dec;20(3):232-242. [PMC free article: PMC7501455] [PubMed: 32994796]

60.Theadom A, Cropley M, Smith HE, Feigin VL, McPherson K. Mind and body therapy for fibromyalgia. Cochrane Database Syst Rev. 2015 Apr 09;2015(4):CD001980. [PMC free article: PMC8409283] [PubMed: 25856658]

61.Bernardy K, Klose P, Busch AJ, Choy EH, Häuser W. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev. 2013 Sep 10;2013(9):CD009796. [PMC free article: PMC6481397] [PubMed: 24018611]

62.Faizan Ejaz K, Wani R, Akbar A, Umaira Khan Q, Ishtiaq H, Amir M, Ali AI, Khan S. Pain Management in Fibromyalgia: Evaluating the Roles of Pregabalin, Duloxetine, and Milnacipran. Cureus. 2024 Dec;16(12):e76631. [PMC free article: PMC11693412] [PubMed: 39744264]

63.Cooper TE, Derry S, Wiffen PJ, Moore RA. Gabapentin for fibromyalgia pain in adults. Cochrane Database Syst Rev. 2017 Jan 03;1(1):CD012188. [PMC free article: PMC6465053] [PubMed: 28045473]

64.Moore A, Bidonde J, Fisher E, Häuser W, Bell RF, Perrot S, Makri S, Straube S. Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews. Rheumatology (Oxford). 2024 Dec 23; [PubMed: 39714260]

65.McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V. Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series. J Pain Res. 2023;16:1993-1998. [PMC free article: PMC10276990] [PubMed: 37337611]

66.Vatvani AD, Patel P, Hariyanto TI, Yanto TA. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Korean J Pain. 2024 Oct 01;37(4):367-378. [PMC free article: PMC11450306] [PubMed: 39344363]

67.Jackson D, Singh S, Zhang-James Y, Faraone S, Johnson B. The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia. Front Psychiatry. 2021;12:593842. [PMC free article: PMC7921161] [PubMed: 33664680]

68.Maddox EK, Massoni SC, Hoffart CM, Takata Y. Dietary Effects on Pain Symptoms in Patients with Fibromyalgia Syndrome: Systematic Review and Future Directions. Nutrients. 2023 Jan 31;15(3) [PMC free article: PMC9921865] [PubMed: 36771421]

69.Badaeva A, Danilov A, Kosareva A, Lepshina M, Novikov V, Vorobyeva Y, Danilov A. Neuronutritional Approach to Fibromyalgia Management: A Narrative Review. Pain Ther. 2024 Oct;13(5):1047-1061. [PMC free article: PMC11393252] [PubMed: 39042252]

70.Zheng C, Zhou T. Effect of Acupuncture on Pain, Fatigue, Sleep, Physical Function, Stiffness, Well-Being, and Safety in Fibromyalgia: A Systematic Review and Meta-Analysis. J Pain Res. 2022;15:315-329. [PMC free article: PMC8820460] [PubMed: 35140516]

71.Dailey DL, Vance CGT, Rakel BA, Zimmerman MB, Embree J, Merriwether EN, Geasland KM, Chimenti R, Williams JM, Golchha M, Crofford LJ, Sluka KA. Transcutaneous Electrical Nerve Stimulation Reduces Movement-Evoked Pain and Fatigue: A Randomized, Controlled Trial. Arthritis Rheumatol. 2020 May;72(5):824-836. [PMC free article: PMC7188591] [PubMed: 31738014]

72.Moshfeghinia R, Shekouh D, Mostafavi S, Hosseinzadeh M, Bahadori AR, Abdollahifard S, Razmkon A. The effects of transcranial direct-current stimulation (tDCS) on pain intensity of patients with fibromyalgia: a systematic review and meta-analysis. BMC Neurol. 2023 Nov 02;23(1):395. [PMC free article: PMC10621179] [PubMed: 37919664]

73.Sun P, Fang L, Zhang J, Liu Y, Wang G, Qi R. Repetitive Transcranial Magnetic Stimulation for Patients with Fibromyalgia: A Systematic Review with Meta-Analysis. Pain Med. 2022 Mar 02;23(3):499-514. [PubMed: 34542624]

74.Affaitati G, Costantini R, Fabrizio A, Lapenna D, Tafuri E, Giamberardino MA. Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain. 2011 Jan;15(1):61-9. [PubMed: 20889359]

75.Nadal-Nicolás Y, Rubio-Arias JÁ, Martínez-Olcina M, Reche-García C, Hernández-García M, Martínez-Rodríguez A. Effects of Manual Therapy on Fatigue, Pain, and Psychological Aspects in Women with Fibromyalgia. Int J Environ Res Public Health. 2020 Jun 26;17(12) [PMC free article: PMC7345776] [PubMed: 32604939]

76.Varni JW, Burwinkle TM, Limbers CA, Szer IS. The PedsQL as a patient-reported outcome in children and adolescents with fibromyalgia: an analysis of OMERACT domains. Health Qual Life Outcomes. 2007 Feb 12;5:9. [PMC free article: PMC1802070] [PubMed: 17295915]

77.Kashikar-Zuck S, Cunningham N, Sil S, Bromberg MH, Lynch-Jordan AM, Strotman D, Peugh J, Noll J, Ting TV, Powers SW, Lovell DJ, Arnold LM. Long-term outcomes of adolescents with juvenile-onset fibromyalgia in early adulthood. Pediatrics. 2014 Mar;133(3):e592-600. [PMC free article: PMC3934334] [PubMed: 24567017]

78.Kashikar-Zuck S, Parkins IS, Ting TV, Verkamp E, Lynch-Jordan A, Passo M, Graham TB. Controlled follow-up study of physical and psychosocial functioning of adolescents with juvenile primary fibromyalgia syndrome. Rheumatology (Oxford). 2010 Nov;49(11):2204-9. [PMC free article: PMC2954368] [PubMed: 20688804]

79.Fitzcharles MA, Da Costa D, Pöyhiä R. A study of standard care in fibromyalgia syndrome: a favorable outcome. J Rheumatol. 2003 Jan;30(1):154-9. [PubMed: 12508406]

80.Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum. 1997 Sep;40(9):1571-9. [PubMed: 9324010]

81.Wolfe F, Ablin J, Baker JF, Diab R, Guymer EK, Littlejohn GO, Michaud K, Rasker JJ, Walitt B, Häuser W. All-cause and cause-specific mortality in persons with fibromyalgia and widespread pain: An observational study in 35,248 persons with rheumatoid arthritis, non-inflammatory rheumatic disorders and clinical fibromyalgia. Semin Arthritis Rheum. 2020 Dec;50(6):1457-1464. [PubMed: 32173059]

82.Treister-Goltzman Y, Peleg R. Fibromyalgia and mortality: a systematic review and meta-analysis. RMD Open. 2023 Jul;9(3) [PMC free article: PMC10335452] [PubMed: 37429737]